

CITATION REPORT

List of articles citing

Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis

DOI: 10.1046/j.1464-410x.2000.00660.x
BJU International, 2000, 86, 80-6.

Source: <https://exaly.com/paper-pdf/42763461/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
34	Prostate adenocarcinoma: cellular and molecular abnormalities. <i>Cancer Control</i> , 2001 , 8, 551-61	2.2	8
33	Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. <i>European Journal of Cancer</i> , 2002 , 38, 1564-79	7.5	397
32	Evaluation of angiogenesis in canine seminomas by quantitative immunohistochemistry. <i>Journal of Comparative Pathology</i> , 2003 , 128, 252-9	1	49
31	Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. <i>European Urology</i> , 2003 , 44, 329-36	10.2	24
30	Lymphangiogenesis in tumors: what do we know?. <i>Microscopy Research and Technique</i> , 2003 , 60, 171-80	2.8	45
29	Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. <i>Annals of Oncology</i> , 2003 , 14, 1525-9	10.3	42
28	Human endocrine gland-derived vascular endothelial growth factor: expression early in development and in Leydig cell tumors suggests roles in normal and pathological testis angiogenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4078-88	5.6	51
27	Transition from preinvasive carcinoma in situ to seminoma is accompanied by a reduction of connexin 43 expression in Sertoli cells and germ cells. <i>Neoplasia</i> , 2006 , 8, 499-509	6.4	47
26	Bevacizumab in a growing teratoma syndrome. Case report. <i>Annals of Oncology</i> , 2007 , 18, 962-3	10.3	37
25	An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors. <i>Anti-Cancer Drugs</i> , 2007 , 18, 273-6	2.4	8
24	Potential therapeutic strategies for lymphatic metastasis. <i>Microvascular Research</i> , 2007 , 74, 145-58	3.7	41
23	Chemotherapy for patients with poor prognosis germ cell tumors. <i>World Journal of Urology</i> , 2009 , 27, 471-6	4	3
22	The role of lymphangiogenesis in lymphatic tumour spread of urological cancers. <i>BJU International</i> , 2009 , 104, 592-7	5.6	13
21	Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009 , 28, 120	12.8	17
20	Vascularization of testicular germ cell tumours: evidence from experimental teratocarcinomas. <i>Journal of Developmental and Physical Disabilities</i> , 2010 , 33, 765-74		12
19	Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. <i>British Journal of Cancer</i> , 2010 , 103, 18-28	8.7	38
18	Genomic gain and over expression of CCL2 correlate with vascular invasion in stage I non-seminomatous testicular germ-cell tumours. <i>Journal of Developmental and Physical Disabilities</i> , 2011 , 34, e114-21; discussion e121		9

17	Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. <i>British Journal of Cancer</i> , 2012 , 107, 1853-63	8.7	30
16	Targeted therapies in the treatment of germ cell tumors: the need for new approaches against "orphan" tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 83, 444-51	7	4
15	Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors. <i>BMC Cancer</i> , 2013 , 13, 382	4.8	17
14	Lymph vessel density in seminomatous testicular cancer assessed with the specific lymphatic endothelium cell markers D2-40 and LYVE-1: correlation with pathologic parameters and clinical outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1386-94	2.8	10
13	Low frequency of HIF-1 α overexpression in germ cell tumors of the testis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013 , 21, 165-9	1.9	5
12	The role of lymph vessel density and lymphangiogenesis in metastatic tumor spread of nonseminomatous testicular germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 178-85	2.8	7
11	Current and future biologic markers for disease progression and relapse in testicular germ cell tumors: a review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 261-71	2.8	12
10	Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer. <i>Brazilian Journal of Medical and Biological Research</i> , 2015 , 48, 13-24	2.8	6
9	Endocrine Gland-Derived Vascular Endothelial Growth Factor/Prokineticin-1 in Cancer Development and Tumor Angiogenesis. <i>International Journal of Endocrinology</i> , 2017 , 2017, 3232905	2.7	9
8	Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance-A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 448-458	2.8	25
7	Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors. <i>Oncology Letters</i> , 2018 , 15, 9852-9860	2.6	8
6	The testicular cancer stem cell niche. <i>Advances in Stem Cells and Their Niches</i> , 2021 , 205-236	0.2	
5	Immune and vascular contributions to organogenesis of the testis and ovary. <i>FEBS Journal</i> , 2021 ,	5.7	5
4	Biology of Germ Cell Tumors. <i>Pediatric Oncology</i> , 2014 , 1-15	0.5	2
3	Evaluation of the Pediatric Urology Patient. 2012 , 3067-3084.e3		5
2	Antiangiogenic drugs as chemosensitizer in genitourinary cancer. 2022 , 85-92		
1	Angioprevention of Urologic Cancers by Plant-Derived Foods.. <i>Pharmaceutics</i> , 2022 , 14,	6.4	0